• - Beobachtung Rituximab HR (95% KI) p-Wert
• -Nach 2 Jahren N=513 N= 505
• + Beobachtung Rituximab HR (95% KI) p-Wert
• +Nach 2 Jahren N=513 N= 505
• - Beobachtung Rituximab HR (95% KI) p-Wert
• -Nach 6 Jahren N= 513 N= 505
• + Beobachtung Rituximab HR (95% KI) p-Wert
• +Nach 6 Jahren N= 513 N= 505
• - CHOP R-CHOP p-Wert
• + CHOP R-CHOP p-Wert
• - ACR-Response Placebo + MTX Rituximab + MTX 2× 1'000 mg Rituximab + MTX 2× 500 mg
• -Studie 1 (WA17042)1 N= 201 RF-positive und -negative Patienten N= 298 RF-positive und -negative Patienten -
• - ACR20 36 (18%) 153 (51%)3 -
• - ACR50 11 (5%) 80 (27%)3 -
• - ACR70 3 (1%) 37 (12%)3 -
• -Studie 2 (WA17043)2 N= 143 RF-positive und -negative Patienten N= 185 RF-positive und -negative Patienten N= 123 RF-positive Patienten
• - ACR20 45 (31%) 96 (52%)4 68 (55%)4
• - ACR50 19 (13%) 61 (33%)4 40 (33%)4
• - ACR70 6 (4%) 28 (15%)4 16 (13%)5
• -Studie 3 (WA16291)2 N= 40 RF-positive Patienten N= 40 RF-positive Patienten -
• - ACR20 15 (38%) 28 (70%)5 -
• - ACR50 5 (13%) 17 (43%)5 -
• - ACR70 2 (5%) 9 (23%)5 -
• + ACR-Response Placebo + MTX Rituximab + MTX 2× 1'000 mg Rituximab + MTX 2× 500 mg
• +Studie 1 (WA17042)1 N= 201 RF-positive und -negative Patienten N= 298 RF-positive und -negative Patienten -
• + ACR20 36 (18%) 153 (51%)3 -
• + ACR50 11 (5%) 80 (27%)3 -
• + ACR70 3 (1%) 37 (12%)3 -
• +Studie 2 (WA17043)2 N= 143 RF-positive und -negative Patienten N= 185 RF-positive und -negative Patienten N= 123 RF-positive Patienten
• + ACR20 45 (31%) 96 (52%)4 68 (55%)4
• + ACR50 19 (13%) 61 (33%)4 40 (33%)4
• + ACR70 6 (4%) 28 (15%)4 16 (13%)5
• +Studie 3 (WA16291)2 N= 40 RF-positive Patienten N= 40 RF-positive Patienten -
• + ACR20 15 (38%) 28 (70%)5 -
• + ACR50 5 (13%) 17 (43%)5 -
• + ACR70 2 (5%) 9 (23%)5 -
• - Placebo + MTX Rituximab + MTX 2× 1’000 mg Rituximab + MTX 2× 500 mg
• + Placebo + MTX Rituximab + MTX 2× 1’000 mg Rituximab + MTX 2× 500 mg
• - Plazebo + MTX Rituximab + MTX (2× 1'000 mg)
• + Plazebo + MTX Rituximab + MTX (2× 1'000 mg)
• - Studie 1 (WA17042) Studie 2 (WA17043)
• + Studie 1 (WA17042) Studie 2 (WA17043)
• -p-Wert* 0,0002
• +p-Wert* 0,0002
• -p-Wert* 0,0015
• +p-Wert* 0,0015
• -p-Wert* <0,0001
• +p-Wert* <0,0001
• -p-Wert* <0,0001
• +p-Wert* <0,0001
• - MabThera (N= 99) Cyclophosphamid (N= 98) Behandlungsunterschied (MabThera – Cyclophosphamid)
• + MabThera (N= 99) Cyclophosphamid (N= 98) Behandlungsunterschied (MabThera – Cyclophosphamid)
• -Roche Pharma (Schweiz) AG, 4153 Reinach.
• +Roche Pharma (Schweiz) AG, Basel.